Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies

Exclusion Criteria

• •Acute myeloid leukemia (AML) \>25% blasts in bone marrow
• •Secondary AML
• •Myelodysplastic syndrome (MDS)
• •Secondary MDS
• •Chronic myeloid leukemia (CML)
• •Juvenile myelomonocytic leukemia (JMML)
• •Paroxysmal nocturnal hemoglobinuria (PNH)
• •Non-Hodgkin's lymphoma (NHL)\*
• •Hodgkin's Disease (HD)\*
• •\*Patients with lymphomas must have failed standard non-cross reactive combination salvage chemotherapy with or without radiation therapy followed by autologous stem cell transplant or patients with chemo resistant disease
• •If patient has had previous stem cell transplant, must not be no earlier than 3 months from previous date of transplant
• •Patients with shortening fraction greater than or equal to 25%
• •Patients with creatinine clearance greater than or equal to 40cc/min/1.73m\^2
• •Patients with FVC greater than or equal to 40% of predicted, or pulse oximetry greater than or equal to 92% on room air
• •Patients with a performance score (Lansky/Karnofsky) of greater than or equal to 50
• •Must have a suitable family member donor that is HIV negative, greater than or equal to 18 years of age available for stem cell donation
• •Patients with a known allergy to murine products
• •(Female Patients) Patient is pregnant
• •Female Patients) Patient is lactating